This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

An Open Label and Safety Study of the Safety Of SPARC1104

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sun Pharma Advanced Research Company Limited
ClinicalTrials.gov Identifier:
NCT01797185
First received: February 16, 2013
Last updated: May 24, 2017
Last verified: December 2016
  Purpose
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis

Condition Intervention Phase
Spasticity Drug: SPARC1104 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Other

Further study details as provided by Sun Pharma Advanced Research Company Limited:

Primary Outcome Measures:
  • No. of participants with adverse events [ Time Frame: 26 weeks ]
  • No. of participants with adverse vital signs [ Time Frame: 26 weeks ]
  • Number of participants with adverse laboratory parameters [ Time Frame: 26 weeks ]

Estimated Enrollment: 100
Actual Study Start Date: April 4, 2013
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SPARC1104 Drug: SPARC1104
Subjects will receive SPARC1104

Detailed Description:
Safety study of SPARC1104
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Willingness to participate and give written informed consent
  • Men and women ≥ 18 years of age
  • Sexually active women who are of child bearing potential will practice an acceptable method of birth control for the duration of the trial as judged by the investigator. Examples of acceptable contraception are: condoms, foams, jellies, diaphragm, intrauterine device, oral or long-acting injected contraceptives, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or having a partner who is incapable of initiating conception. The practice of contraception must have started at least 3 months prior to trial entry.
  • If female, negative pregnancy test result at Screening
  • Diagnosed with MS and a known history of spasticity
  • Meet one of the following criteria

    • Subjects who completed the double-blind randomized withdrawal phase (Part 3) of trial CLR_09_21 with no major protocol violation
    • Subjects who are newly diagnosed with spasticity due to MS with no history of treatment using any anti-spasticity medications, or, with a history of spasticity due to MS but with no previous exposure to baclofen treatment
    • Subjects who are receiving a stable baclofen IR dose (ie, a dose of 10 mg to 80 mg daily, having started at least 30 days prior to enrollment)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01797185

  Show 51 Study Locations
Sponsors and Collaborators
Sun Pharma Advanced Research Company Limited
  More Information

Responsible Party: Sun Pharma Advanced Research Company Limited
ClinicalTrials.gov Identifier: NCT01797185     History of Changes
Other Study ID Numbers: CLR_11_04
Study First Received: February 16, 2013
Last Updated: May 24, 2017

Keywords provided by Sun Pharma Advanced Research Company Limited:
baclofen, spasticity

Additional relevant MeSH terms:
Muscle Spasticity
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on July 19, 2017